# US Sacroiliitis Market > US Sacroiliitis Market Research Report By Diagnosis (Imaging Tests, Anesthetic Injections), By Treatment (Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation) and By End User (Hospitals, Diagnostic Centers) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.96% - **2024:** $ 184.8 Million - **2025:** $ 203.21 Million - **2035:** $ 525 Million - **Key Players:** AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR), UCB S.A. (BE) **Report ID:** MRFR/Pharma/18488-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-sacroiliitis-market-20035 --- ## Market Summary ## **US Sacroiliitis Market Overview** The US Sacroiliitis Market is currently influenced by several key market drivers. There is a growing incidence of autoimmune diseases, specifically ankylosing spondylitis, which leads to an increased prevalence of sacroiliitis. Advances in diagnostic techniques, such as MRI and ultrasound, are facilitating early detection of sacroiliitis, leading to timely interventions. ### **Key US Sacroiliitis Market Trends Highlighted** Moreover, the rise in the aging population is fueling demand for effective treatment options for chronic pain conditions linked to sacroiliitis. Opportunities to be explored in this market include the development of novel therapeutics and biologics tailored for sacroiliitis patients. As the understanding of the disease process improves, there is room for innovative treatment modalities, including personalized medicine approaches. Increased research funding and collaboration between academic institutions and pharmaceutical companies can also drive advancement in this area. Furthermore, expanding telemedicine services can enhance patient access to specialists, especially in rural areas of the US where access to healthcare may be limited. Trends in recent times show a heightened focus on patient-centered treatment plans that consider the unique needs and preferences of individuals suffering from sacroiliitis. This shift is contributing to greater patient compliance and satisfaction with treatment regimens. There is also an increased emphasis on non-pharmacological therapies, including physical therapy and lifestyle modifications, as adjuncts to medication. The rise in awareness campaigns about sacroiliitis is encouraging patients to seek help earlier, which may improve outcomes. In summary, the US Sacroiliitis Market is evolving with a focus on innovative treatments, personalized care, and greater accessibility, driven by increased awareness and advancements in medical technology. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Sacroiliitis Market Drivers** ### **Rising Prevalence of Autoimmune Disorders** The increasing prevalence of autoimmune disorders, particularly ankylosing spondylitis, is a significant driver for the US [Sacroiliitis Market](../../../reports/sacroiliitis-market-6290) Industry. According to the National Institutes of Health, autoimmune diseases have increased by approximately 20% over the past decade, impacting more than 24 million people in the United States. This rise directly contributes to the incidences of sacroiliitis, as conditions like ankylosing spondylitis lead to inflammation in the sacroiliac joint. Organizations such as the American College of Rheumatology focus on research and treatment guidelines to manage these diseases, directly affecting the market demand for sacroiliitis therapies and diagnostic tools. As more individuals are diagnosed with these conditions, the market for sacroiliitis will likely expand, reflecting the need for effective treatments and supportive care in the US. ### **Advancements in Diagnostic Imaging Technologies** Advancements in diagnostic imaging technologies such as Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT) scans have significantly boosted the US Sacroiliitis Market Industry. The American Radiological Society reports that the usage of advanced imaging techniques has grown by over 30% in the last five years, leading to earlier and more accurate diagnosis of sacroiliitis. This early detection facilitates timely intervention, thus improving patient outcomes and increasing the demand for related medical services and treatments. Major imaging companies like GE Healthcare and Siemens Healthineers are continuously innovating to enhance the precision of imaging technologies, encouraging healthcare providers to utilize these diagnostics more frequently. ### **Growing Awareness and Education about Sacroiliitis** The growing awareness and education about sacroiliitis, its symptoms, and treatment options is another vital driver for the US Sacroiliitis Market Industry. In recent years, public health campaigns, supported by organizations like the Arthritis Foundation, have increased awareness about the signs and symptoms of sacroiliitis. Reports indicate that over 60% of patients are now more knowledgeable about the condition compared to five years ago. This knowledge encourages patients to seek medical attention sooner, thereby contributing to an increase in diagnosis rates and subsequent treatment demands. Furthermore, advances in telemedicine have made it easier for patients to consult with healthcare providers, thus enhancing the chances for timely diagnosis and treatment of sacroiliitis. ### **Increase in Chronic Pain Disorders** The rise in chronic pain disorders among the American population significantly influences the US Sacroiliitis Market Industry. According to the Centers for Disease Control and Prevention, approximately 20% of adults in the United States suffer from chronic pain conditions, with sacroiliitis contributing to chronic lower back and pelvic pain. As more patients experience pain associated with the sacroiliac joints, healthcare professionals are increasingly diagnosing sacroiliitis, which stimulates demand for targeted medications and interventions. Pharmaceutical companies are investing in Research and Development (R&D) to produce specialized treatments, which will likely cater to the growing population of patients experiencing this condition. This upward trend in chronic pain incidences continuously drives the market for sacroiliitis management solutions, reflecting a growing need for effective therapies. ## **US Sacroiliitis Market Segment Insights** ### **Sacroiliitis Market Diagnosis Insights** The US Sacroiliitis Market segment focusing on Diagnosis demonstrates robust growth potential fueled by advancements in diagnostic techniques and technology. Imaging Tests such as MRI and CT scans play a fundamental role in the diagnosis of sacroiliitis, helping healthcare professionals visualize inflammation and structural abnormalities in the sacroiliac joints effectively. These tests have become increasingly important as they provide detailed insights into a patient's condition, encouraging timely and accurate treatment interventions. Meanwhile, Anesthetic Injections are essential in both the diagnostic process and pain management for sacroiliitis patients. By temporarily blocking pain signals, these injections not only aid in symptom relief but also assist healthcare providers in distinguishing between sacroiliitis and other conditions. The growing recognition of sacroiliitis's impact on patients’ quality of life is driving the demand for early diagnosis and appropriate interventions. This emphasis on robust diagnostic capabilities is significantly influencing the overall US Sacroiliitis Market revenue. Moreover, the ongoing advancements in imaging technologies and minimally invasive procedures are expected to contribute positively, offering greater precision and patient comfort. Market statistics indicate that these diagnostic methods are critical for achieving optimal treatment outcomes and enhancing patient satisfaction. Furthermore, as awareness of sacroiliitis continues to evolve within the medical community and in public health discussions, it could lead to a heightened focus on research and innovation in diagnostic methodologies tailored to improve patient care in the US. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Sacroiliitis Market Treatment Insights** The Treatment segment of the US Sacroiliitis Market encompasses various approaches aimed at alleviating pain and improving quality of life for patients suffering from this condition. Medications play a critical role in pain management and anti-inflammatory effects, significantly influencing patient outcomes. Joint Injections offer targeted relief, as they deliver corticosteroids directly into the affected area, showing immediate benefits for many patients. Joint Fusion serves as a more invasive option for individuals with severe joint damage, providing long-term stability and pain relief, which is essential for those who do not respond to conservative treatments. Additionally, Radiofrequency Denervation is an innovative approach that disrupts nerve signals responsible for pain, offering significant relief and functioning efficiently without surgery. Each of these methods caters to different levels of severity and patient preferences, highlighting the diverse strategies within the Treatment segment. The rising prevalence of sacroiliitis and the demand for effective pain management solutions in the US contributes to the ongoing growth and evolution of this market segment, reflecting a strong focus on improving patient care through tailored therapeutic options. As the understanding of sacroiliitis deepens, improvements in treatment methodologies are likely to emerge, further refining the approach to managing this complex condition. ### **Sacroiliitis Market End User Insights** The US Sacroiliitis Market exhibits significant potential within the End User segment, primarily driven by increased healthcare access and advancements in treatment options. Hospitals serve as a crucial hub for managing sacroiliitis cases, providing comprehensive care through advanced diagnostic and therapeutic capabilities. This segment's strength stems from the greater availability of specialists and state-of-the-art technologies, enhancing patient outcomes. On the other hand, Diagnostic Centers are gaining traction, offering specialized diagnostic tools that facilitate early and accurate detection of sacroiliitis. The growing number of outpatient services in these centers supports better patient convenience and faster service delivery. Furthermore, trends show a rising emphasis on personalized treatment plans, fostering an opportunity for both Hospitals and Diagnostic Centers to innovate and tailor services. Challenges, such as managing increasing healthcare costs and necessitated reimbursement policies, are paving the way for strategic adaptations within the segment. Overall, the importance of diverse End Users in effectively addressing sacroiliitis reflects a growing recognition of the need for specialized care pathways in the US healthcare industry. ## **US Sacroiliitis Market Key Players and Competitive Insights** The US Sacroiliitis Market presents a dynamic landscape characterized by increasing prevalence of sacroiliitis, which has led to heightened demand for effective therapies and treatment options. Several pharmaceutical companies are competing aggressively to capture market share, with research and development playing vital roles in driving innovation and addressing the unmet needs of patients. Key players in this market focus on developing biologics, small molecules, and supportive therapies targeting various aspects surrounding inflammatory diseases associated with sacroiliitis. Competitive strategies involve collaborations, partnerships, and strategic acquisitions aimed at expanding product portfolios and enhancing the overall efficacy of treatments for this debilitating condition. As a result, ongoing advancements in medical science coupled with aggressive marketing tactics have intensified the competition within this evolving market. Bristol Myers Squibb has established a notable presence in the US Sacroiliitis Market through its commitment to advancing therapies that address serious inflammatory conditions. The company is recognized for its robust research initiatives and a portfolio of innovative products that demonstrate significant effectiveness in treating sacroiliitis and similar diseases. With a strong emphasis on transforming patient care, Bristol Myers Squibb excels in navigating clinical trials and regulatory approval processes, showing its ability to swiftly bring new therapies to the market. Its collaborations with healthcare professionals and institutions further enhance its understanding of patient needs, allowing the company to position itself as a trusted resource in the management of sacroiliitis. By leveraging scientific expertise and a dedication to patient-centric solutions, Bristol Myers Squibb is well-equipped to maintain and grow its influence in the competitive landscape of the US Sacroiliitis Market. Novartis plays a crucial role in the US Sacroiliitis Market, recognized for its comprehensive suite of products aimed at treating inflammatory conditions including sacroiliitis. The company boasts a strong market presence bolstered by a range of therapies that have demonstrated efficacy in managing symptoms and improving quality of life for patients. Key products offered by Novartis include biologics and treatment alternatives that cater specifically to the inflammatory pathways associated with sacroiliitis. The company actively engages in research partnerships and strategic mergers and acquisitions that enhance its product offerings and expand its market reach. With a commitment to advancing its portfolio through innovative therapies and a focus on patient outcomes, Novartis's strength lies not only in its established products but also in its future potential driven by ongoing research and development initiatives tailored to the needs of US patients experiencing sacroiliitis. ### **Key Companies in the US Sacroiliitis Market Include** ## **US Sacroiliitis Market Industry Developments** Recently, the US Sacroiliitis Market has seen notable developments with companies such as Bristol Myers Squibb, Novartis, AstraZeneca, and Merck making strides in the treatment landscape. The FDA has been evaluating new drug applications for therapies targeting sacroiliitis, spurred by growing patient demand for better management solutions. In terms of mergers and acquisitions, Eli Lilly completed its acquisition of Dermira in May 2023, enhancing its product portfolio relevant to inflammatory conditions, including sacroiliitis. Furthermore, June 2023 witnessed Gilead Sciences gaining a competitive edge through its acquisition of MiroBio, aiming at innovative immunology approaches. Market growth is fueled by increasing investments in Research and Development, along with positive clinical trial results from companies such as AbbVie and Takeda Pharmaceutical. This has led to an upswing in stock valuations and heightened interest from investors. The historical landscape also includes significant activities, such as Pfizer's launch of its biologic approved in January 2022 specifically for ankylosing spondylitis, bridging a gap in therapy options. Collectively, this paints a dynamic picture of ongoing advancements and strategic movements shaping the US Sacroiliitis Market. ## **US Sacroiliitis Market Segmentation Insights** ### **Sacroiliitis Market Diagnosis Outlook** ### **Sacroiliitis Market Treatment Outlook** ### **Sacroiliitis Market End User Outlook** ## Market Drivers ### Rising Demand for Personalized Medicine The shift towards personalized medicine is influencing the sacroiliitis market significantly. Tailored treatment plans based on genetic and biomarker profiles are becoming more prevalent, allowing for more effective management of sacroiliitis. This trend is supported by the increasing availability of genetic testing and biomarker identification technologies. The US personalized medicine market was valued at around $350 billion in 2023, indicating a robust growth trajectory. As healthcare providers adopt personalized approaches, the demand for specific therapies targeting sacroiliitis is likely to increase, thereby enhancing market dynamics. ### Increasing Prevalence of Autoimmune Disorders The rising incidence of autoimmune disorders, including ankylosing spondylitis and psoriatic arthritis, is likely to drive the sacroiliitis market. According to recent estimates, autoimmune diseases affect approximately 24 million individuals in the US, with a notable percentage experiencing sacroiliitis as a complication. This growing patient population necessitates enhanced diagnostic and therapeutic options, thereby propelling market growth. The sacroiliitis market is expected to benefit from increased healthcare spending, which reached $4.1 trillion in 2023, as more patients seek treatment for their conditions. As awareness of these disorders expands, healthcare providers are more likely to recognize and diagnose sacroiliitis, further contributing to market expansion. ### Technological Innovations in Diagnostic Tools Advancements in imaging technologies, such as MRI and CT scans, are transforming the diagnostic landscape for sacroiliitis. These innovations enable earlier and more accurate detection of the condition, which is crucial for effective treatment. The sacroiliitis market is poised to grow as healthcare facilities increasingly adopt these advanced diagnostic tools. In 2023, the imaging market in the US was valued at approximately $20 billion, with a significant portion allocated to musculoskeletal imaging. Enhanced diagnostic capabilities not only improve patient outcomes but also drive demand for targeted therapies, thereby fostering growth in the sacroiliitis market. ### Enhanced Patient Education and Support Programs The establishment of patient education and support programs is likely to influence the sacroiliitis market positively. These initiatives aim to empower patients with knowledge about their condition, treatment options, and self-management strategies. As healthcare providers recognize the importance of patient engagement, more resources are being allocated to these programs. In 2023, approximately 60% of healthcare organizations in the US reported implementing patient education initiatives. By fostering a better understanding of sacroiliitis, these programs may lead to earlier diagnosis and treatment, ultimately driving growth in the sacroiliitis market. ### Growing Investment in Biologics and Targeted Therapies Investment in biologics and targeted therapies is a key driver of the sacroiliitis market. These innovative treatments have shown promise in managing inflammation and pain associated with sacroiliitis. The US biologics market was estimated to reach $300 billion in 2023, reflecting a strong interest in developing new therapies. As pharmaceutical companies focus on research and development, the introduction of novel biologics is expected to expand treatment options for patients suffering from sacroiliitis. This influx of new therapies may lead to increased competition and improved patient outcomes, further stimulating market growth. ## Future Outlook The [Sacroiliitis Market](https://www.marketresearchfuture.com/reports/sacroiliitis-market-6290) is projected to grow at a 9.96% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising healthcare expenditure. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in AI-driven diagnostic tools for early detection - Expansion of targeted biologic therapies for personalized treatment By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient access. ## Segment Insights ### By Application: Diagnostic Imaging (Largest) vs. Functional Imaging (Fastest-Growing) In the US sacroiliitis market, the application segment is primarily dominated by Diagnostic Imaging, which holds the largest market share among its counterparts. Functional Imaging follows closely behind, making significant strides in its adoption within the clinical setting. Cardiac Imaging and Oncology Imaging constitute smaller segments but remain integral in specific use cases, particularly as supportive imaging modalities in comprehensive patient management. Overall, the distribution reflects a trend towards sophisticated imaging solutions that meet diverse diagnostic needs. The growth trends in this segment are driven by technological advancements and increasing demand for early diagnosis of conditions leading to sacroiliitis. Consequently, there is a marked move towards Functional Imaging methods that allow for more detailed and informative assessments. As healthcare providers seek to enhance diagnostic accuracy and patient outcomes, investments in advanced imaging technologies are anticipated to accelerate rates of adoption across the board, establishing a more robust market presence for emerging modalities. Diagnostic Imaging (Dominant) vs. Functional Imaging (Emerging) Diagnostic Imaging serves as the cornerstone of the application segment in the US sacroiliitis market. This method encompasses established imaging techniques that enable clinicians to diagnose sacroiliitis effectively, ensuring precise identification of the condition. The reliability and accuracy of Diagnostic Imaging have secured it as the dominant modality. In contrast, Functional Imaging is quickly emerging as a vital complement to traditional methods, offering enhanced insights into physiological processes and disease progression. With its ability to assess the functional aspects of sacroiliitis, this segment is gaining traction, appealing to a broader base of clinical applications. As both segments evolve, their synergy is expected to amplify the effectiveness of patient management strategies, ultimately benefiting healthcare providers and patients alike. ### By Type: Closed MRI Systems (Largest) vs. Open MRI Systems (Fastest-Growing) In the US sacroiliitis market, the distribution among MRI systems reveals Closed MRI Systems as the leading segment, favored for their superior image quality and diagnostic capabilities. Open MRI Systems, while smaller in market share, are gaining traction due to their patient-friendly design and comfort, attracting a growing user base who may be claustrophobic or larger in size. The growth trends in this segment are significantly influenced by advancements in imaging technology and increasing prevalence of sacroiliitis, prompting healthcare providers to invest in modern imaging solutions. Closed MRI Systems are expected to maintain their dominance as they evolve, while Open MRI Systems are rapidly emerging due to changing patient needs, offering a competitive edge in the market. Closed MRI Systems (Dominant) vs. Open MRI Systems (Emerging) Closed MRI Systems are characterized by their robust imaging capabilities, providing high-resolution images essential for accurate diagnosis of sacroiliitis. These systems are widely adopted in clinical settings due to their reliability and precision, making them the dominant choice among healthcare providers. In contrast, Open MRI Systems are emerging as a viable alternative, appealing to patients who seek a more comfortable scanning experience. They allow for easier access and less anxiety during procedures, which is increasingly important in today’s healthcare environment. The comparative accessibility and evolving technology in Open MRI Systems are propelling their growth, positioning them as a strong competitor to Closed MRI Systems in the US sacroiliitis market. ### By Field Strength: High Field MRI (Largest) vs. Low Field MRI (Fastest-Growing) In the US sacroiliitis market, the market share distribution among the field strength segment demonstrates a significant dominance of High Field MRI. This technology is widely regarded for its superior imaging capabilities, leading to a sizable portion of market penetration. In contrast, Low Field MRI is gaining traction, as healthcare facilities increasingly seek cost-effective and accessible imaging solutions. As the awareness of its benefits rises, its share in the market is expected to grow. Growth trends indicate that Low Field MRI is emerging as a preferred option among smaller clinics due to its affordability and ease of use. This segment's rise is fueled by advancements in technology that enhance imaging quality despite its lower field strength. Meanwhile, High Field MRI continues to thrive due to its robust performance in diagnosing sacroiliitis, ensuring a balanced competitive landscape within the segment. High Field MRI (Dominant) vs. Low Field MRI (Emerging) High Field MRI represents the dominant segment of the field strength category, well-known for its exceptional imaging quality and resolution, making it invaluable for diagnosing complex conditions such as sacroiliitis. This technology is favored in large hospitals due to its accuracy and detailed imaging capabilities. As the market evolves, High Field MRI is also benefiting from continuous improvements in technology, further solidifying its position. On the other hand, Low Field MRI is emerging as a competitive alternative, particularly appealing to smaller facilities looking to manage costs while still providing reliable services. With advancements in MRI technology reducing the gap in image quality, Low Field MRI is poised to capture a growing share of the market by addressing the needs of various healthcare providers. ### By End User: Hospitals (Largest) vs. Diagnostic Imaging Centers (Fastest-Growing) In the US sacroiliitis market, the distribution of market share among end users reveals that hospitals hold the largest segment, reflecting their critical role in patient treatment and management. Diagnostic imaging centers follow closely, benefiting from advancements in imaging technologies that enhance diagnostic accuracy. Research institutes, while essential for innovation and research, represent a smaller share, focusing primarily on developing new therapies and understanding the disease better. The reliance on hospitals for comprehensive care underpins their leading position in this market. Growth trends indicate a bright future for diagnostic imaging centers, driven by an increasing prevalence of sacroiliitis and a growing emphasis on early diagnosis. Technological advancements, including MRI and CT scan improvements, are propelling these centers to the forefront. Hospitals, while dominant, are also investing in better facilities and training to cater to rising patient numbers. Research institutes, although emerging at a slower pace, are gaining traction through partnerships that enhance clinical applications and therapies, reflecting an evolving landscape in the US sacroiliitis market. Hospitals (Dominant) vs. Diagnostic Imaging Centers (Emerging) Hospitals play a dominant role in the US sacroiliitis market due to their comprehensive treatment capabilities and facilities that support various medical disciplines. Their extensive resources and expert staff allow them to manage complex cases effectively. In contrast, diagnostic imaging centers are emerging as significant players, focusing on specific diagnostic technologies that improve the detection and management of sacroiliitis. These centers utilize state-of-the-art imaging solutions, which are vital for accurate diagnosis, and they offer a more streamlined approach to imaging than traditional hospital settings. This specialization positions them well for growth, especially as awareness of early diagnosis continues to increase. Together, these segments complement each other, catering to the full spectrum of patient needs. ## Competitive Benchmarking The sacroiliitis market exhibits a competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AbbVie Inc (US), Amgen Inc (US), and Johnson & Johnson (US) are actively shaping the market dynamics. AbbVie Inc (US) has positioned itself as a leader through its robust pipeline of biologics aimed at inflammatory conditions, indicating a strong commitment to research and development. Meanwhile, Amgen Inc (US) has been focusing on expanding its therapeutic offerings through strategic collaborations, which may enhance its market presence. Johnson & Johnson (US), with its diversified portfolio, appears to leverage its extensive distribution network to optimize market penetration, thereby influencing competitive strategies across the sector.The business tactics employed by these companies reflect a concerted effort to localize manufacturing and optimize supply chains, which are crucial in a moderately fragmented market. This competitive structure allows for a variety of players to coexist, yet the influence of major companies remains pronounced. Their ability to adapt to local market needs while maintaining global standards is likely to be a key factor in sustaining their competitive edge. In October AbbVie Inc (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel treatment for sacroiliitis. This collaboration is expected to enhance AbbVie’s research capabilities and accelerate the development of innovative therapies, potentially positioning the company at the forefront of the market. The strategic importance of this partnership lies in its potential to leverage combined expertise, thereby expediting the delivery of effective treatments to patients. In September Johnson & Johnson (US) launched a new digital health platform aimed at improving patient engagement and treatment adherence for those suffering from sacroiliitis. This initiative underscores the company's commitment to integrating technology into healthcare solutions, which may enhance patient outcomes and foster loyalty. The strategic significance of this move is evident in its alignment with current trends towards digitalization in healthcare, potentially setting a benchmark for competitors. In August Amgen Inc (US) expanded its manufacturing capabilities in the US to support the production of its biologic therapies for inflammatory diseases, including sacroiliitis. This expansion is indicative of Amgen's strategy to enhance supply chain reliability and meet growing demand. The implications of this development suggest a proactive approach to market needs, which could strengthen Amgen's competitive position in the long term. As of November the competitive trends in the sacroiliitis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into treatment protocols. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing operational efficiencies. Looking ahead, it appears that competitive differentiation will likely evolve from traditional price-based strategies to a focus on technological advancements, innovative therapies, and reliable supply chains, thereby redefining the parameters of success in this market. ## Recent News & Developments Recently, the US Sacroiliitis Market has seen notable developments with companies such as Bristol Myers Squibb, Novartis, AstraZeneca, and Merck making strides in the treatment landscape. The FDA has been evaluating new drug applications for therapies targeting sacroiliitis, spurred by growing patient demand for better management solutions. In terms of mergers and acquisitions, Eli Lilly completed its acquisition of Dermira in May 2023, enhancing its product portfolio relevant to inflammatory conditions, including sacroiliitis. Furthermore, June 2023 witnessed Gilead Sciences gaining a competitive edge through its acquisition of MiroBio, aiming at innovative immunology approaches. Market growth is fueled by increasing investments in Research and Development, along with positive clinical trial results from companies such as AbbVie and Takeda Pharmaceutical. This has led to an upswing in stock valuations and heightened interest from investors. The historical landscape also includes significant activities, such as Pfizer's launch of its biologic approved in January 2022 specifically for ankylosing spondylitis, bridging a gap in therapy options. Collectively, this paints a dynamic picture of ongoing advancements and strategic movements shaping the US Sacroiliitis Market. ## Report Scope | MARKET SIZE 2024 | 184.8(USD Million) | | --- | --- | | MARKET SIZE 2025 | 203.21(USD Million) | | MARKET SIZE 2035 | 525.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.96% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR), UCB S.A. (BE) | | Segments Covered | Application, Type, Field Strength, End User | | Key Market Opportunities | Advancements in biologics and personalized medicine enhance treatment options in the sacroiliitis market. | | Key Market Dynamics | Rising demand for innovative therapies drives competitive dynamics in the evolving sacroiliitis market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US sacroiliitis market in 2024?** A: The market valuation was $184.8 Million in 2024. **Q: What is the projected market valuation for the US sacroiliitis market by 2035?** A: The projected valuation for 2035 is $525.0 Million. **Q: What is the expected CAGR for the US sacroiliitis market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period is 9.96%. **Q: Which companies are considered key players in the US sacroiliitis market?** A: Key players include AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Pfizer Inc, Roche Holding AG, Sanofi S.A., and UCB S.A. **Q: What are the main application segments in the US sacroiliitis market?** A: Main application segments include Diagnostic Imaging, Functional Imaging, Cardiac Imaging, and Oncology Imaging. **Q: What was the valuation range for the Oncology Imaging segment in 2024?** A: The valuation range for the Oncology Imaging segment was $89.8 Million to $260.0 Million. **Q: What types of MRI systems are included in the US sacroiliitis market?** A: Types of MRI systems include Closed MRI Systems, Open MRI Systems, and Extremity MRI Systems. **Q: What is the projected valuation range for High Field MRI systems by 2035?** A: The projected valuation range for High Field MRI systems is $104.8 Million to $290.0 Million. **Q: Which end users are significant in the US sacroiliitis market?** A: Significant end users include Hospitals, Diagnostic Imaging Centers, and Research Institutes. **Q: What was the valuation range for Hospitals as end users in 2024?** A: The valuation range for Hospitals as end users was $70.0 Million to $200.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-sacroiliitis-market-20035*